Indian Pharma Market Registers 8.7% Growth in January: Report

The growth was primarily driven by cardiac (10.9%), anti-diabetic (10.2%), and gastrointestinal (6.9%) therapies, which saw the highest value increases among key therapeutic areas.

The Indian pharmaceutical market (IPM) recorded an 8.7% growth in January 2025.

The growth was primarily driven by cardiac (10.9%), anti-diabetic (10.2%), and gastrointestinal (6.9%) therapies, which saw the highest value increases among key therapeutic areas, according to market research firm Pharmarack.

In addition to value growth, the report highlighted a 2.4% increase in unit sales during the month.

The moving annual turnover (MAT) for IPM, covering February 2024 to January 2025, showed an 8.3% increase, bringing the total market turnover to over INR 2.23 trillion.

Meanwhile, unit growth in the domestic market stood at 0.6% during the same period.

Top Pharma Players & Best-Selling Drugs

Several leading pharmaceutical companies experienced notable value growth in January 2025. Among the top 20 players in the industry, Torrent Pharma (15.7%), Sun Pharma (13.7%), Eris Lifesciences (13.7%), Intas (13.2%), and Dr Reddy’s (10.4%) posted significant monthly value gains, benefiting from increased demand and bonus unit sales at full value.

In terms of drug sales, GSK’s antibiotic Augmentin and USV’s anti-diabetic Glycomet GP remained the top-selling brands, both for January and in the MAT figures. Augmentin recorded sales of INR 825 Cr, while Glycomet GP followed with INR 797 Cr over the last 12 months.

Additionally, therapy areas such as cardiac, gastrointestinal, and anti-infectives, which make up approximately 37% of IPM, saw robust annual growth of 11.2%, 10%, and 5.8%, respectively.

A notable trend in the industry has been the continuous decline in active pharmaceutical ingredient (API) prices over the past several months.

While this has led to improved margins for Indian drug manufacturers, industry insiders have expressed concerns about potential predatory pricing strategies by Chinese suppliers.

Experts warn that sustained price suppression could impact domestic API production and long-term supply chain stability.